Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.

Original research
par
Wu, Li-Tzy et al

Date de publication

2023

Géographie

USA

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Oui

Évalué par des pairs

Yes

L’objectif

Pharmacy administration and dispensing of methadone treatment for opioid use disorder (PADMOUD) may address inadequate capability of opioid treatment programs (OTPs) in the US by expanding access to methadone at community pharmacies nationally. There is no published US study on OUD patients’ perspectives on PADMOUD.

Constatations/points à retenir

Participants reported feasibility of taking the tablet formulation of methadone at the pharmacy and identified benefits from PADMOUD (e.g., better access, efficiency, convenience) compared with usual care at the OTP. Participants perceived support for PADMOUD from their family/friends, OTP staff, and pharmacy staff. PADMOUD was perceived to be a great option for stable patients with take-home doses and those with transportation barriers. The distance (convenience), office hours, and the cost were considered factors most influencing their decision to receive methadone from a pharmacy. Nonjudgmental communication, pharmacists’ training on methadone treatment, selection of patients (stable status), workflow of PADMOUD, and protection of privacy were considered key factors for improving operations of PADMOUD.

La conception ou méthodologie de recherche

Interviews (n=17)

Mots clés

About pharmacists
About PWUD
Substitution/OAT